Location: Canton

120 Oakside Court
Suite H
Canton, Georgia 30114
Tel: (678) 785-9600
Fax: (877) 380-2077
This study is to assess LDL-C reductions at Week 52 with monthly (Q4W [≤31 days]) dosing of LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with very-high risk for CVD on a stable diet and oral LDL-C lowering drug therapy.
Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, St. Augustine
Condition: Cholesterol, Heart Disease
This study is to assess LDL-C reductions at Week 52 with monthly (Q4W [≤31 days]) dosing of LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with CVD, or at high risk for CVD, on a stable diet and oral LDL-C lowering drug therapy
Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, St. Augustine
Condition: Cholesterol, Heart Disease
This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with underlying heterozygous familial hypercholesterolemia (HeFH) and/or ASCVD to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to diet and maximally tolerated lipid-lowering therapy.
Location(s): Canton, Jacksonville (Headquarters), Jacksonville - LaVilla (Downtown), Lake City, Macon, St. Augustine
Condition: Cholesterol, Heart Disease
IMPACT2: In-Home Study with MiniMed™ 780G Pump Automated Con …
Location(s): Canton, Jacksonville - LaVilla (Downtown)
Condition: Diabetes
Efficacy and safety of LY3209590 compared to Degludec in adu …
Location(s): Canton, Jacksonville - LaVilla (Downtown)
Condition: Diabetes